Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkin's Lymphoma
Date:8/21/2007

e product may qualify for seven years of marketing exclusivity in the United States.

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in two Phase I/II clinical trials, in combination with Vidaza(R) for hematological malignancies and with Gemzar(R) in solid tumors, and in four Phase II monotherapy clinical trials in hematological malignancies.

About Hodgkin's Lymphoma

Hodgkin's lymphoma (HL) is a cancer of the lymphatic system that begins in the lymph nodes and progresses to other organs, including the lungs, liver, bone and bone marrow. It is characterized by the presence of Reed-Sternberg cells. Currently, there is no known cause of the disease, but epigenetic alterations, including histone acetylation, have been identified. In addition, the Epstein-Barr virus, HIV and familial history are known risk factors. The disease is slightly more prevalent in men than women, and the median age of diagnosis is 38.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I/II combination trials with Vidaza(R) and Gemzar(R)
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... Scheduled for Friday, May 4, at 9:00 a.m.,Eastern ... 2007 /PRNewswire-FirstCall/ --,Medivation, Inc. today announced that new ... disease patients in the Company's,six-month Phase 2 efficacy ... compared with placebo-treated patients on,all five efficacy endpoints ...
... Homspera Shows Promise As an Adjuvant for ... Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR,BioSciences ... its influenza vaccine adjuvant study being performed ... host,immune responsiveness above that induced by vaccine ...
Other Medicine Technology:Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4
(Date:12/15/2009)... Palo Alto Networks(TM), the network security ... its PA-4000 Series next-generation firewalls for accurate threat ... visibility and control over applications such as peer-to-peer ... national university with eight facilities on five campuses. ... a number of academic schools and institutions throughout ...
(Date:12/15/2009)... Lourdes Health Care Services Inc., the parent company of ... United States $7.95 million to resolve allegations that the ... two hospitals are Our Lady of Lourdes Medical Center ... Burlington County (LMC) in Willingboro, N.J. ,, LMC ... whistleblower, Tony Kite, in 2005. The lawsuit alleged that ...
(Date:12/15/2009)... dementia risk, research finds , , TUESDAY, Dec. 15 (HealthDay ... that regulates appetite, may guard against Alzheimer,s disease, new ... this may be one of many agents that we ... senior study author Dr. Sudha Seshadri, an associate professor ... it may be one of many markers that we ...
(Date:12/15/2009)... released some sobering statistics concerning the parallel rise in diabetes and ... effective means of combating this trend afflicting their workforce. , ... ... diabetes are climbing across America due in large part to the ... Diabetes Association has stated that the rate of diabetes could be ...
(Date:12/15/2009)... Dec. 15 Knowledge ... the pharmaceutical and bio-tech research market with ... Over the past 11 years CMR has ... Consulting Network (PCN®), which now includes 70,000 ... both primary care and hard-to-reach specialties. ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Parent Company of Two New Jersey Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2
... Nonin Medical, Inc., a leading,innovator of physiological monitoring ... Best of CES 2009 award for the Onyx(R) ... first wireless fingertip oximeter,the innovative device combines Bluetooth(R) ... enabling individuals to accurately,monitor vital signs. , ...
... CASACALIFANO CONTINUES AS CHAIRMANNEW YORK, Jan. 15 The ... Columbia University announced today that Join Together(TM) ... Ph.D., will become the President and Chief Executive Officer ... Califano, Jr., the former U.S. Secretary of Health, Education, ...
... care policy and government relations firms to provide integrated ... in WashingtonWASHINGTON, Jan. 15 EBG Advisors, Inc. and ... Health Advisors, LLC, a strategic alliance of the public ... health care law firms, and a leading government relations ...
... that in spite of their universal health care system ... in the United Kingdom are less willing to undergo ... the Britons perceive greater societal stigma from diagnosis of ... 125 older adults in Indianapolis and 120 older adults ...
... Jan. 15 "Before increasing federal spending on health ... privacy rule to ensure individuals have control over their ... the Institute for Health Freedom (IHF). "Right now, ... ensure true patient privacy," Blevins stresses. ...
... Settlement reimburses patients and physicians who have been shortchanged ... The American Medical Association (AMA), along with the Medical ... Missouri State Medical Association, claims victory with the settlement ... Group. The $350 million settlement marks the largest monetary ...
Other Medicine News:Health News:Nonin Medical's Onyx(R) II, Model 9560 Receives Bluetooth SIG's Best of CES 2009 Award 2Health News:Join Together(tm) Merges Into CASA* 2Health News:Join Together(tm) Merges Into CASA* 3Health News:EBG Advisors and Oldaker Group Form National Health Advisors 2Health News:Does universal health care affect attitude toward dementia? 2Health News:Economic Stimulus Package Could Impinge on Americans' Health Privacy 2Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: